Patent intelligence · US
US 11020365
Mixture of fatty acids for use in the treatment of inflammatory pathologies
Mixture of fatty acids for use in the treatment of inflammatory pathologies
Patent details — US 11020365
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 1, 2021
- Expiration
- May 27, 2041
- Applicant
- AGAIN LIFE ITALIA SRL
- Claims
- 34
- CPC classes
- A61K, A61K31/20, A61K31/201, A61K31/202
Quick answer
US 11020365 (Mixture of fatty acids for use in the treatment of inflammatory pathologies) is held by AGAIN LIFE ITALIA SRL. Status: granted. Granted Jun 1, 2021. Expires May 27, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AGAIN LIFE ITALIA SRL
- Grant date
- Expiration
- Claims
- 34
- CPC classes
- A61K, A61K31/20, A61K31/201, A61K31/202, A61K45/06, A61K9/08
More from AGAIN LIFE ITALIA SRL
Related pharmaceutical patents in our USPTO index.
-
US 12370232
Use of polyphenol containing sugar cane extracts for preventing, improving or treating a skin condition
granted -
US 12201701
Vegetable oil-derived contrast agent with high stability and preparation method thereof
granted -
US 11730178
Extraction method
granted -
US 11311581
Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions
granted -
US 10960000
Abuse resistant pharmaceutical compositions
granted -
US 10646523
Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions
granted -
US 10213389
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
granted
Frequently asked questions
What is US patent 11020365?
US 11020365 (Mixture of fatty acids for use in the treatment of inflammatory pathologies) is held by AGAIN LIFE ITALIA SRL. Status: granted. Granted Jun 1, 2021. Expires May 27, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11020365?
AGAIN LIFE ITALIA SRL is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 27 pharmaceutical patents for this assignee.
When does US 11020365 expire?
Our index shows an expiration date of May 27, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.